Alembic Pharma Q3: Consolidated PAT Dips, Standalone Growth Soars

OTHER
Whalesbook Logo
AuthorAarav Shah|Published at:
Alembic Pharma Q3: Consolidated PAT Dips, Standalone Growth Soars
Overview

Alembic Pharmaceuticals reported mixed Q3 FY26 results, with consolidated revenue up 10.84% to ₹1,876 Cr, but PAT fell 3.94% to ₹133 Cr due to exceptional items. Standalone operations excelled, seeing revenue rise 16.79% and PAT surge 33.40%. Margins improved across both segments. A Non-Executive Director appointment was also approved.

📉 The Financial Deep Dive

  • The Numbers: Alembic Pharmaceuticals Limited reported its Q3 FY26 financial results, showcasing a mixed performance. Consolidated revenue grew by a healthy 10.84% YoY to ₹1,876.31 Cr. However, consolidated Profit After Tax (PAT) experienced a marginal decline of 3.94% YoY to ₹132.97 Cr. This dip was primarily influenced by an exceptional item of ₹42.23 Cr recognized in Q3 FY26, related to the impact of new Labour Codes. In contrast, Q3 FY25 had an exceptional income of ₹12.87 Cr from an insurance claim.
  • Standalone Strength: On a standalone basis, the company demonstrated robust performance. Revenue surged by 16.79% YoY to ₹1,642.24 Cr, and standalone PAT saw a significant increase of 33.40% YoY to ₹114.47 Cr from ₹85.81 Cr in Q3 FY25.
  • The Quality: Operating margins showed improvement. The consolidated EBITDA margin (before exceptional items) expanded to 16.42% in Q3 FY26, up from 16.00% YoY. Standalone operations were even stronger, with EBITDA margins jumping to 17.19% from 13.89% YoY, indicating enhanced operational efficiency and cost management. For the nine months ended December 31, 2025, consolidated revenue grew 12.13% YoY to ₹5,497.18 Cr, and PAT increased by 10.68% to ₹472.07 Cr. However, standalone nine-month PAT decreased by 7.11% to ₹397.36 Cr.
  • Balance Sheet & Liquidity: Key financial health indicators remain stable. Consolidated Debt-Equity ratio was 0.25 and standalone D/E was 0.23 as of December 31, 2025, suggesting a manageable debt profile. Consolidated interest coverage ratio stood at 7.93 times for Q3 FY26, down from 8.99 times in Q3 FY25. Standalone interest coverage improved significantly to 7.41 times from 5.76 times YoY.

🚩 Risks & Outlook

The consolidated PAT decline, albeit explained by exceptional items, warrants investor attention. Furthermore, the drop in consolidated interest coverage ratio requires monitoring. While standalone performance is a strong positive, the decline in standalone nine-month PAT is a point to watch. Investors will focus on the sustainability of standalone growth and the management's ability to navigate consolidated challenges and one-off impacts in the coming quarters. The appointment of Mr. Rajkumar Baheti as a Non-Executive Non-Independent Director, effective April 1, 2026, provides continuity in leadership.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.